Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
It May Be Possible That Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) CEO Compensation Could Get Bumped Up
Key Insights Jilin Province Huinan Changlong Bio-pharmacy to hold its Annual General Meeting on 28th of May CEO Hong Zhang's total compensation includes salary of CN¥273.0k The total compensation
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Jilin Changlong Pharmaceutical (08049) will pay a special dividend of 0.0625 yuan per share on July 16
Jilin Changlong Pharmaceutical (08049) announced that the company will pay a special dividend per share on July 16, 2024...
JILIN CHANGLONG: PROPOSED DECLARATION AND PAYMENT OF A SPECIAL DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS
JILIN CHANGLONG: NOTICE OF BOARD OF DIRECTORS'' MEETINGANDPROPOSED DECLARATION AND PAYMENT OFA SPECIAL DIVIDEND
Jilin Changlong Pharmaceutical (08049) announced annual results. Profit attributable to shareholders of 148 million yuan decreased by 23.43% year-on-year
Jilin Changlong Pharmaceutical (08049) announced results for the year ended December 31, 2023, and the group obtained revenue...
JILIN CHANGLONG: ANNUAL REPORT 2023
JILIN CHANGLONG: 2023 ANNUAL RESULTS ANNOUNCEMENT
Jilin Changlong Pharmaceutical (08049.HK): subscribed to 100 million yuan structured deposit products from ICBC
Gelonghui March 12, 丨 Jilin Changlong Pharmaceutical (08049.HK) issued an announcement. On March 12, 2024, the company subscribed to structured deposit products from the Industrial and Commercial Bank of China for an amount of RMB 10 million.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Guotai Junan: The pharmaceutical industry has a low market risk appetite and selects “cost-effective” stocks with steady management
Guotai Junan released a research report saying that the high base effect in COVID-related fields dissipated throughout the year, and the growth rate is expected to gradually return to its own path, but Q1, especially in January-February, was still affected by the base effect of the epidemic.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Improved Earnings Required Before Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049) Stock's 25% Jump Looks Justified
The Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049) share price has done very well over the last month, posting an excellent gain of 25%. The last 30 days bring the annual g
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
No Data